Patents by Inventor Barry L. Dowell

Barry L. Dowell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20120135429
    Abstract: A method for classifying cancer patients as eligible to receive cancer therapy with a Bcl-2 inhibitor comprising determination of the presence or absence in a patient tissue sample of levels of pro-GRP, as a surrogate marker for the presence of chromosomal copy number gain at chromosomal locus 18q21-q22. The classification of cancer patients based upon pro-GRP levels as a surrogate for the presence or absence of 18q21-q22 gain allows selection of patients to receive chemotherapy with a Bcl-2 family inhibitor, either as monotherapy or as part of combination therapy, and to monitor patient response to such therapy using a peripheral blood sample.
    Type: Application
    Filed: December 1, 2011
    Publication date: May 31, 2012
    Inventors: Evelyn M. McKeegan, Barry L. Dowell, Rick R. Lesniewski, Dimitri Semizarov
  • Publication number: 20120115745
    Abstract: The present disclosure relates generally to the evaluation and/or treatment of a subject having or suspected of having a neoplastic condition, and in particular to the use of biomarkers for identifying patients receptive to a certain drug therapy, and which permit monitoring of patient response to such therapy.
    Type: Application
    Filed: November 9, 2011
    Publication date: May 10, 2012
    Inventors: Evelyn M. McKeegan, Peter Ansell, Barry L. Dowell, Ke Zhang, Viswanath Devanarayan, Arunava Charkravartty
  • Publication number: 20100233175
    Abstract: The present invention relates to antibodies that may be used, for example, in the diagnosis, treatment and prevention of haepatocellular carcinoma (HCC), liver cancer and related conditions.
    Type: Application
    Filed: March 10, 2009
    Publication date: September 16, 2010
    Applicant: ABBOTT LABORATORIES
    Inventors: Toru Yoshimura, Barry L. Dowell, Gangamani S. Beligere, Qiaoqiao Ruan
  • Publication number: 20100136711
    Abstract: To provide a more convenient and more accurate method of assaying ProGRP by improving the stability of ProGRP which is known to be unstable in a biological sample. By using a blood sample in a condition in which a blood coagulation factor is not activated is used as a sample, the degradation of ProGRP is suppressed, whereby it is possible to store a sample for a long period of time and to improve the accuracy of an assay.
    Type: Application
    Filed: December 11, 2007
    Publication date: June 3, 2010
    Inventors: Toru Yoshimura, Kenju Fujita, Barry L. Dowell
  • Publication number: 20080160545
    Abstract: A method for classifying cancer patients as eligible to receive cancer therapy with a Bcl-2 inhibitor comprising determination of the presence or absence in a patient tissue sample of levels of pro-GRP, as a surrogate marker for the presence of chromosomal copy number gain at chromosomal locus 18q21-q22. The classification of cancer patients based upon pro-GRP levels as a surrogate for the presence or absence of 18q21-q22 gain allows selection of patients to receive chemotherapy with a Bcl-2 family inhibitor, either as monotherapy or as part of combination therapy, and to monitor patient response to such therapy using a peripheral blood sample.
    Type: Application
    Filed: December 28, 2006
    Publication date: July 3, 2008
    Applicant: Abbott Laboratories
    Inventors: Evelyn M. McKeegan, Barry L. Dowell, Rick R. Lesniewski, Dimitri Semizarov
  • Patent number: 5672480
    Abstract: The present invention relates to the field of cancer immunoassay. Specifically, a new immunoassay method for prostate specific antigen (PSA) is presented. Also presented is a complex which resembles a complex of PSA and .alpha.-antichymotrypsin (ACT) that can be used as a calibrator or control in an immunoassay for PSA. Further presented is a method for fractionating polyclonal antibodies, to PSA, into those which bind epitopes that are masked by the binding of PSA to ACT and those which do not bind such epitopes.
    Type: Grant
    Filed: May 23, 1995
    Date of Patent: September 30, 1997
    Assignee: Abbott Laboratories
    Inventors: Barry L. Dowell, Debra B. Alexander, Susan B. O'Morchoe, Carol A. King, Allan H. Smith
  • Patent number: 5599677
    Abstract: The present invention relates to the field of cancer immunoassay. Specifically, a new immunoassay method for prostate specific antigen (PSA) is presented. Also presented is a complex which resembles a complex of PSA and .alpha.-antichymotrypsin (ACT) that can be used as a calibrator or control in an immunoassay for PSA. Further presented is a method for fractionating polyclonal antibodies, to PSA, into those which bind epitopes that are masked by the binding of PSA to ACT and those which do not bind such epitopes.
    Type: Grant
    Filed: December 29, 1993
    Date of Patent: February 4, 1997
    Assignee: Abbott Laboratories
    Inventors: Barry L. Dowell, Carol A. King, Debra B. Alexander, Allan H. Smith, Susan B. O'Morchoe